|
| NSCLC | SCLC | ||||||||
| Stage: | 1 + 2 | 3 | 4 | LD | ED | |||||
| Gender: | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male |
|
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
|
| 124 (43%) | 165 (57%) | 141 (33%) | 281 (67%) | 222 (43%) | 298 (57%) | 49 (45%) | 59 (55%) | 56 (35%) | 102 (65%) |
| Age: <70 | 68 (55%) | 67 (41%) | 68 (48%) | 109 (39%) | 130 (59%) | 149 (50%) | 35 (71%) | 33 (56%) | 34 (61%) | 46 (45%) |
| ≥70 | 56 (45%) | 98 (59%) | 73 (52%) | 172 (61%) | 92 (41%) | 149 (50%) | 14 (29%) | 26 (44%) | 22 (39%) | 56 (55%) |
| Performance status: 0-1 | 105 (85%) | 128 (78%) | 86 (61%) | 153 (54%) | 71 (32%) | 96 (32%) | 30 (61%) | 44 (74%) | 17 (30%) | 25 (25%) |
| 2-4 | 19 (15%) | 37 (22%) | 55 (39%) | 128 (46%) | 151 (68%) | 202 (68%) | 19 (39%) | 15 (26%) | 39 (70%) | 77 (75%) |
| Time period: |
|
|
|
|
|
|
|
|
|
|
| 1989-1993 | 14 (22%) | 51 (78%) | 17 (18%) | 80 (82%) | 33 (36%) | 59 (64%) | 13 (30%) | 31 (70%) | 10 (29%) | 24 (71%) |
| 1994-1998 | 30 (42%) | 42 (58%) | 24 (28%) | 62 (72%) | 38 (38%) | 61 (62%) | 13 (54%) | 11 (46%) | 12 (31%) | 27 (69%) |
| 1999-2003 | 29 (47%) | 33 (53%) | 42 (37%) | 71 (63%) | 71 (48%) | 78 (52%) | 10 (50%) | 10 (50%) | 14 (37%) | 24 (63%) |
| 2004-2008 | 51 (57%) | 39 (43%) | 58 (46%) | 68 (54%) | 80 (44%) | 100 (56%) | 13 (65%) | 7 (35%) | 20 (43%) | 27 (57%) |
| Lung cancer type: |
|
|
|
|
|
|
|
|
|
|
| Squamous cell carcinoma | 25 (20%) | 69 (42%) | 29 (21%) | 107 (38%) | 28 (13%) | 87 (29%) |
|
|
|
|
| Adenocarcinoma | 71 (57%) | 57 (35%) | 79 (56%) | 109 (39%) | 147 (66%) | 143 (48%) |
|
|
|
|
| Other lung cancera | 12 (10%) | 22 (13%) | 20 (14%) | 34 (12%) | 30 (14%) | 43 (15%) |
|
|
|
|
| Carcinoid | 12 (10%) | 5 (3%) | 3 (2%) | 0 | 1 | 0 |
|
|
|
|
| Clinical lung cancer | 4 (3%) | 12 (7%) | 10 (7%) | 31 (11%) | 16 (7%) | 25 (8%) |
|
|
|
|
| Primary therapy: |
|
|
|
|
|
|
|
|
|
|
| Surgery ± RTb ± Chemoc | 99 (80%) | 119 (72%) | 32 (23%) | 40 (14%) | 2 | 1 | 4 (8%) | 5 (9%) |
|
|
| Curative RT ± Chemo | 9 (7%) | 14 (9%) | 26 (18%) | 47 (17%) |
|
| 34 (69%)d | 38 (64%)d |
|
|
| Palliative RT ± Chemo | 5 (4%)e | 10 (6%)e | 24 (17%) | 66 (24%) | 39 (18%) | 56 (19%) | 3 (5%) | 2 (2%) | ||
| Chemo ± palliative RT | 28 (20%) | 40 (14%) | 107 (48%) | 120 (40%) | 9 (18%) | 14 (24%) | 47 (84%) | 76 (75%) | ||
| No therapy | 11 (9%) | 22 (13%) | 31 (22%) | 88 (31%) | 74 (33%) | 121 (41%) | 2 (4%) | 2 (3%) | 6 (11%) | 24 (23%) |